PreventAGE Now Provides Precise Measurement of Advanced Glycation and Oxidation Products for Your Research Program

Dear Investigator,

PreventAGE Health Care is pleased to be the first to offer analyses of a unique set of advanced glycation and oxidation products to academic researchers.

Our precision diagnostic tests will be useful as you seek to understand mechanistic pathways resulting in diabetic complications and will provide you with important predictive information on risk and potential targets for new therapies. This analytical service can also add value to understanding any number of degenerative physical outcomes. Our assays can be applied to multiple research applications, in multiple fields.

While our overarching objective is to fundamentally change the care of patients with diabetes and thereby improve their outcomes, including quality of life, health status, and longevity, we believe that there are multiple connections between the biomarkers we are able to isolate and degenerative diseases.  We believe that our diagnostic assays will fill an essential, yet currently unmet, need and will lead to the fulfillment of our mission "Know your risk, Change your outcome!".

We are excited about the potential for our unique services in multiple areas of clinical investigation, and welcome inquiries to discuss application to your projects.


Paul J. Beisswenger MD, Chief Scientific Officer, PreventAGE Healthcare


Glycation/Oxidation Pathways Play a Major Role in the Development of Diabetic Complications

The vascular complications of diabetes are major health problems in the US and in the developed world, involving all ethnic populations. 

One of the most important processes associated with the cellular dysfunction associated with hyperglycemia is nonenzymatic glycation, which has gained increasing acceptance as a significant mechanism contributing to the vascular damage associated with diabetes [1-4]. This process initially involves spontaneous reactions between ubiquitous reducing sugars, and amines, while its extent depends only on the nature and concentration of the reactants. It initially involves the formation of early glycation products (EGPs) including Amadori Products and highly reactive α dicarbonyl compounds (methylglyoxal (MG) and others), which in turn undergo a complex series of chemical reactions that lead to the formation of advanced glycation end products (AGEs) [5-6]. Glucose induced oxidative stress is also initiated in diabetes and can produce direct tissue damage or lead to activation of all of the major pathways that produce diabetic complications [7-10].


We Now Provide Assays to Measure Specific AGEs and Oxidation Products

Until recently, our knowledge of the full spectrum of AGEs and oxidation products formed in diabetes has been limited, but using liquid chromatography, triple quaudrupole mass spectrometric methods (LC-MS/MS) we can now precisely measure 6 specific AGEs and 4 stable oxidation products. The structural formulae of these products, which range in molecular weight from 161.2 to 378.4 Daltons are shown in figure 1. These AGEs reflect and integrate the activity of distinct precursor glycation and oxidative pathways, and provide new tools to assess the impact of increased production, or decreased detoxification, of these products over time. We have developed new analytical methods, which can quantify multiple AGEs and OPs on substantially shortened runs, allowing 28,000 analyses per year for each instrument acquired.


Figure 1. Structural Formulae of AGEs and oxidation End Products


The Magnitude of Increase in AGEs and Oxidation Products in Diabetes

Utilizing these assays, we have shown that the highest in vivo AGEs quantitatively are arginine derived end products, which increase up to 9 fold in plasma, and 15 fold in urine in diabetes [11,12], while we have also recently shown that urinary and plasma levels of methionine sulfoxide (MetSO) increase five-fold in diabetes relative to controls.


Methylylglyoxal (MG) Can Predict Individual Susceptibility to the Development of Diabetic Nephropathy

It is well recognized that individuals with diabetes show widely varying susceptibility to the development of debilitating vascular complications [13-15]. Thus a substantial subset (25-35 %) of those with diabetes develop diabetic kidney disease (DKD) despite reasonable glycemic control while others never develop them in spite of long-term hyperglycemia [16, 17]. We have previously shown in several study populations that those with higher levels of α dicarbonyls and oxidative stress have a greater propensity to accelerated DKD [8, 18, 19]. The concurrent increases in dicarbonyl and oxidative stress seen in our human translational studies are consistent with Brownlee’s [20] proposed unifying hypothesis of diabetes complications.  Biomarkers that reflect these pathways could therefore identify those at greatest risk of DKD .


Methylglyoxal Derived AGEs Predict Diabetic Nephropathy

Our breakthrough was the development of LC-MS/MS methods to measure specific long-lived advanced glycation end products (AGEs) that reflect reactive sugar precursors and applying them to landmark clinical outcome studies of type 1 and 2 diabetes. [21] We demonstrated in our initial outcome study that three plasma AGE biomarkers, two of which are end products of MG, predict development of biopsy proven early DKD [27]. Although these AGEs reflect different chemical processes than HbA1C, these biomarkers together have additive predictive value concurrently with it.


PreventAGE Has Multiple Confirmatory Outcome Studies including Prediction of Diabetic Cardiovascular Disease

We have now confirmed these studies in two additional outcome studies, including DCCT/EDIC. These findings show that the specific AGEs that we found to be predictive for DKD have a high potential as biomarkers for the inherent propensity for developing other diabetic complications. As shown in our bibliography on this web site, we have now performed outcome studies for CVD in type 1 and 2 diabetes which show that specific oxidative products are strongly predictive for cardiac endpoints.

We believe that the development of new biomarkers for prediction of diabetic complications will shift the treatment paradigms for diabetes. The development of diagnostic tests that predict complications early, before disease is visible is a valuable research tool and will ultimately allow individualized treatment yielding more positive results, healthier patients, and lower health care costs. Additionally, enhanced understanding of the roles that AGEs and OPs play as biomarkers will open doors to future research on the role that they play in creating complications.

PreventAGE's goal is to create assays that will provide important predictive information to researchers, doctors and patients with diabetes, allowing them to establish treatment plans that assure better and more cost effective outcomes.

We are excited about the potential for our unique services in multiple areas of clinical investigation, and welcome inquiries to discuss application to your projects.



  1. Bucala, R. and A. Cerami, Advanced glycosylation: Chemistry, biology,  and implications for diabetes and aging. Adv. in Pharm., 1992. 23: p. 1-34.
  2. Brownlee, M., Glycation products and the pathogenesis of diabetic complications. Diabetes Care, 1992. 15(12): p. 1835-43.
  3. Monnier, V.M., The Maillard Reaction in Aging , Diabetes and Nutrition. Prog in Clin and Biol Res, 1989. 304: p. 1-22.
  4. Bunn, H.F. and P.J. Higgins, Reaction of monosaccharides with proteins.  Possible evolutionary significance. Science, 1981. 213: p. 222-24.
  5. Thornalley, P.J., Clinical Significance of Glycation. Clin. Lab., 1999. 45: p. 263-273.
  6. Thornalley, P.J., S. Battah, N. Ahmed, N. Karachalias, S. Agalou, R. Babaei-Jadidi, and A. Dawnay, Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochemical Journal, 2003. 375(Pt 3): p. 581-92.
  7. Brownlee, M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 2005. 54(6): p. 1615-25.
  8. Baynes, J. and S. Thorpe, Role of Oxidative Stress in Diabetic Complications: A New Perspective on an Old Paradigm. Diabetes, 1999. 48: p. 1-9.
  9. Hink, U., H. Li, H. Mollnau, M. Oelze, E. Matheis, M. Hartmann, M. Skatchkov, F. Thaiss, R.A. Stahl, A. Warnholtz, T. Meinertz, K. Griendling, D.G. Harrison, U. Forstermann, and T. Munzel, Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circulation Research, 2001. 88(2): p. 2.
  10. Nishikawa, T., D. Edelstein, X. Du, S. Yamagishi, T. Matsumura, Y. Kaneda, M. Yorek, D. Beebe, P. Oates, H. Hammes, I. Giardino, and M. Brownlee, Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic  damage. Nature, 2000. 404: p. 787-790.
  11. Ahmed, N., R. Babaei-Jadidi, S. Howell, P. Beisswenger, and P. Thornalley, Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia, 2005. 48: p. 1590-1603.
  12. Ahmed, N., R. Babaei-Jadidi, S. Howell, P. Thornalley, and P. Beisswenger, Glycated and oxidised protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care, 2005. 28: p. 2465-2471.
  13. DCCT Research Group, Clustering of Long-Term Complications in Families With Diabetes in the Diabetes Control and Complications Trial. Diabetes, 1997. 46: p. 1829-1839.
  14. Fioretto, P., M.W. Steffes, J. Barbosa, S.S. Rich, M.E. Miller, and M. Mauer, Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. Diabetes, 1999. 48(4): p. 865-9.
  15. Seaquist, E.R., F.C. Goetz, S. Rich, and J. Barbosa, Familial Clustering of Diabetic Kidney Disease: Evidence for Genetic Susceptibility to Diabetic Nephropathy. N Engl J Med, 1989. 320: p. 1161-5.
  16. Borch-Johnsen, K., K. Norgaard, E. Hommel, E.R. Mathiesen, J.S. Jensen, T. Deckert, and H.H. Parving, Is diabetic nephropathy an inherited complication? Kidney International, 1992. 41(4): p. 719-22.
  17. Krolewski, A.J., J.H. Warram, R. Kahn, L.I. Kahn, and C.R. Kahn, Epidemiologic Approach to the Etiology of Type I Diabetes Mellitus and its Complications. New Eng J Med, 1987. 18: p. 267-273.
  18. Beisswenger, P., K. Drummond, R. Nelson, S. Howell, B. Szwergold, and M. Mauer, Susceptibility To Diabetic Nephropathy Is Related To Dicarbonyl And Oxidative Stress. Diabetes, 2005. 54: p. 3274-3281.
  19. Rosen, P., P. Nawroth, G. King, W. Moller, H. Trischler, and L. Packer, The Role of Oxidative Stress in the onset and Progression of Diabetes and its Complications: A Summary of a Congress Series Sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes/Metabolism Research and Reviews, 2001. 17: p. 189-212.
  20. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature., 2001. 414(6865): p. 813-20.
  21. Beisswenger, P.J., S. Howell, M. Mauer, G. Russell, M. Miller, and S. Rich, Early Progression of Diabetic Nephropathy correlates with Methylglyoxal Derived Advanced Glycation End Products (AGEs). Diabetes Care, 2013. 36, Published Ahead of Print, online June 18, 2013: p. 3234-3239.
  22. Weil, E.J., G. Fufaa, L.I. Jones, T. Lovato, K.V. Lemley, R.L. Hanson, W.C. Knowler, P.H. Bennett, B. Yee, B.D. Myers, and R.G. Nelson, Effect of Losartan on Prevention and Progression of Early Diabetic Nephropathy in American Indians With Type 2 Diabetes. Diabetes, 2013. 62: p. 3224–3231.
  23. Baynes, J.W., The Maillard hypothesis on aging: time to focus on DNA. [Review] [20 refs]. Annals of the New York Academy of Sciences., 2002. 959: p. 360-7.
  24. Monnier, V.M. and A. Cerami, Nonenzymatic Browning in Vivo: Possible Process for Aging of Long-lived Proteins. Science, 1981. 211: p. 491-493.
  25. Thornalley, P.J., Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems--role in ageing and disease. [Review] [112 refs]. Drug Metabolism & Drug Interactions, 2008. 23(1-2): p. 125-50.
  26. GIBBS, W.W., Medicine gets up close and personal. Nature Medicine, 2014. 506: p. 144-145.
  27. Cai, W., M. Ramdas, L. Zhu, X. Chen, G.E. Striker, and H. Vlassara, Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin. PNAS, 2012. online at 1073/pnas.1205847109/-/DCSupplemental.
  28. Kellow, N. and G. Savige, Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: a systematic review. European Journal of Clinical Nutrition, 2013. 67 p. 239–248.
  29. Cai, W., J. Uribarri, L. Zhu, X. Chen, S. Swamy, Z. Zhao, F. Grosjean, C. Simonaro, G.A. Kuchel, M. Schnaider-Beeri, M. Woodward, G.E. Striker, and H. Vlassara, Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. PNAS early addition, 2012. PNAS.
  30. Baynes, J.W. and S.R. Thorpe, Glycoxidation and lipoxidation in atherogenesis. [Review] [73 refs]. Free Radical Biology & Medicine., 2000. 28(12): p. 1708-16.
  31. Monnier, V.M., D.R. Sell, and S. Genuth, Glycation products as markers and predictors of the progression of diabetic complications. [Review] [78 refs]. Annals of the New York Academy of Sciences, 2005. 1043(The Maillard Reaction: Chemistry at the Interface of Nutrition, Aging, and Disease): p. 567-581.
  32. Beisswenger, P. and D. Ruggiero-Lopez, Metformin inhibition of glycation processes. Diabetes and Metabolism, 2003. 29: p. 6S95-6S103.
  33. Rabbani, N., M.V. Chittari, C.W. Bodmer, D. Zehnder, A. Ceriello, and P.J. Thornalley, Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes, 2010. 59(4): p. 1038-45.
  34. Bowden, D.W., A.J. Cox, B.I. Freedman, C.E. Hugenschimdt, L.E. Wagenknecht, D. Herrington, S. Agarwal, T.D. Register, J.A. Maldjian, M.C.-Y. Ng1, F.-C. Hsu, C.D. Langefeld, J.D. Williamson, and J.J. Carr, Review of the Diabetes Heart Study (DHS) Family of Studies: A Comprehensively Examined Sample for Genetic and Epidemiological Studies of Type 2 Diabetes and its Complications. The Review of Diabetic Studies, 2010. 7(3): p. 188-201.
  35. Nathan, D.M., P.A. Cleary, J.Y. Backlund, S.M. Genuth, J.M. Lachin, T.J. Orchard, P. Raskin, B. Zinman, C. Diabetes, I. Complications Trial/Epidemiology of Diabetes, and G. Complications Study Research, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.[see comment]. New England Journal of Medicine, 2005. 353(25): p. 2643-53.
  36. Vulesevic, B., B. McNeill, C. Ghem, R. Milne, and E. Suuronen, Over-expression of glyoxalase-1 in vascular cells prevents development of heart failure in a mouse model of type 1 diabetes. Biochemical Society Proceedings from the "Glyoxalase Centennial : 100 Years of Glyoxalase Research and Emergence of Dicarbonyl Stress", University of Warwick, UK, 2013.